Is Novo Nordisk (NYSE:NVO) Reasonable After Its 58% Fall?

Simply Wall St.11-04 21:19

Novo Nordisk has seen its share price fall sharply in recent years, even as attention stays fixed on its diabetes and obesity franchise. With the stock down heavily over a 3 year window, the key issue...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2680050348?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351","is_english":true,"pubTime":"2026-11-04 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2680050348","market":"sg","top_or_hot":-1,"title":"Is Novo Nordisk (NYSE:NVO) Reasonable After Its 58% Fall?","media":"Simply Wall St.","content":"<div>\n<p>Novo Nordisk has seen its share price fall sharply in recent years, even as attention stays fixed on its diabetes and obesity franchise. With the stock down heavily over a 3 year window, the key issue...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/is-novo-nordisk-nysenvo-reasonable-after-its-58-fall\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Novo Nordisk (NYSE:NVO) Reasonable After Its 58% Fall?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Novo Nordisk (NYSE:NVO) Reasonable After Its 58% Fall?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-04 21:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/is-novo-nordisk-nysenvo-reasonable-after-its-58-fall><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk has seen its share price fall sharply in recent years, even as attention stays fixed on its diabetes and obesity franchise. With the stock down heavily over a 3 year window, the key issue...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/is-novo-nordisk-nysenvo-reasonable-after-its-58-fall\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOH","symbol_name":"Novo Nordisk A/S B Shares ADRhedged","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/is-novo-nordisk-nysenvo-reasonable-after-its-58-fall","article_id":"2680050348","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/is-novo-nordisk-nysenvo-reasonable-after-its-58-fall","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2680050348","pubTimestamp":1793798366,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 4, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4007":"制药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","PPH":"VanEck Pharmaceutical ETF","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","NVOX":"2倍做多NVO ETF-Defiance","NVO":"诺和诺德","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","OZEM":"Roundhill GLP-1 & Weight Loss ETF","BK4532":"文艺复兴科技持仓","NVOC":"Corgi NVO 2x Daily ETF","BK4599":"减肥药"},"translate_title":"诺和诺德（纽约证券交易所股票代码：NVO）下跌 58% 后合理吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOH":0.6,"PPH":0.6,"NVOX":0.6,"NVO":1.98,"NVOC":0.6,"THNR":0.6,"OZEM":0.6},"content_text":"Novo Nordisk has seen its share price fall sharply in recent years, even as attention stays fixed on its diabetes and obesity franchise. With the stock down heavily over a 3 year window, the key issue for anyone looking at Novo Nordisk today is whether the current valuation lines up with what its earnings can support.  The share price has fallen 58.0% over the past 3 years, which puts the focus squarely on whether the earnings profile still backs the market value placed on the business. Recent news around tougher GLP-1 competition and new products such as CagriSema can influence how investors think about future profitability, which feeds directly into how much they are willing to pay for Novo Nordisk's earnings stream today. The analysts covering Novo Nordisk have run their own numbers. See what analysts think Novo Nordisk's shares could be worth.  The stock's next move may depend on whether Novo Nordisk's current earnings, and realistic expectations for those earnings, are enough to justify the price investors are paying today. If you are weighing Novo Nordisk after a 58.0% 3 year share price decline and tough GLP-1 competition, it can help to compare that earnings story with 35 high quality undervalued stocks. AdvertisementIs Novo Nordisk a Bargain on Earnings? The P/E ratio is a useful lens for Novo Nordisk because earnings still anchor how investors think about its drug portfolio. On this measure, the stock trades on about 10.2x earnings, which is well below the pharmaceuticals industry average of roughly 16.2x and far under the broader peer group around 59.6x. That is a wide gap for a global healthcare player with a large diabetes and obesity platform. The fair value framework, which blends factors like Novo Nordisk's margins, scale and risk profile, points to a higher P/E than where the shares change hands today. As a result, the current multiple screens as undervalued against that tailored benchmark. Because recent headlines focus on tougher GLP-1 competition and ambitious 2030 targets, the discount suggests investors may be pricing in a cautious outlook despite solid current earnings support. Explore the numbers behind Novo Nordisk's P/E valuation. NYSE:NVO P/E Ratio as at Nov 2026 The Novo Nordisk Narrative: What Would Justify Today's Price? Novo Nordisk's valuation story raises a simple question that Narratives try to answer directly. Narratives on Simply Wall St's Community page set out the specific paths for Novo Nordisk's future growth, margins and earnings that would need to hold for the current share price to look meaningfully cheap or expensive. This turns a single ratio or model output into a concrete set of expectations you can monitor over time. One of the top community narratives on Novo Nordisk: 58% undervalued \"While sentiment is weak and valuation has compressed to roughly mid-teens forward earnings, Novo has added an important de-risking catalyst...\" Discover why this Narrative puts Novo Nordisk at 58% undervalued. Novo Nordisk’s price is only one side of the decision The people setting Novo Nordisk’s priorities and the way their rewards line up with your interests can matter as much as any P/E chart you see. See who runs Novo Nordisk and how they are paid. This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Novo Nordisk might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2680050348","isCrawlerRequest":true}